Skip to content

Ponoi Management, LLC

Follow

13F filer, CIK 1720702, San Francisco, CA

Ponoi Management, LLC reported $73,242,000 across 4 holdings for the quarter ended 2022-09-30, in a 13F-HR filed 2022-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-22-012318

Period
2022-09-30
Reported value
$73.2M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q3 2022

Share positions as resolved from 13F-HR 0000950123-22-012318, largest first. % of portfolio is the value over $73,242,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 1,599,417 shares; 2021Q1: 1,599,417 shares; 2021Q2: 1,599,417 shares; 2021Q3: 1,599,417 shares; 2021Q4: 1,599,417 shares; 2022Q1: 1,599,417 shares; 2022Q2: 1,599,417 shares; 2022Q3: 1,599,417 shares 1,599,417$38.5M52.54%0
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 1,298,908 shares; 2021Q1: 1,298,908 shares; 2021Q2: 1,298,908 shares; 2021Q3: 1,298,908 shares; 2021Q4: 1,298,908 shares; 2022Q1: 1,298,908 shares; 2022Q2: 1,298,908 shares; 2022Q3: 1,298,908 shares 1,298,908$17M23.2%0
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 685,011 shares; 2021Q1: 685,011 shares; 2021Q2: 685,011 shares; 2021Q3: 685,011 shares; 2021Q4: 685,011 shares; 2022Q1: 685,011 shares; 2022Q2: 685,011 shares; 2022Q3: 685,011 shares 685,011$13.5M18.44%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: 686,274 shares; 2021Q1: 686,274 shares; 2021Q2: 686,274 shares; 2021Q3: 561,573 shares; 2021Q4: 327,122 shares; 2022Q1: 327,122 shares; 2022Q2: 327,123 shares; 2022Q3: 327,123 shares 327,123$4.26M5.82%0Timeline

How Q3 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-22-012318 base2022-11-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0000950123-22-012318 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0000950123-22-008911 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0000950123-22-006492 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0000950123-22-002169 Quarter ended 2021-12-312022-02-11acceptance time not in the bulk data set
13F-HR 0000950123-21-014997 Quarter ended 2021-09-302021-11-12acceptance time not in the bulk data set
13F-HR 0000950123-21-011526 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0000950123-21-007097 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0000950123-21-002048 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-NT 0000950123-20-010829 Quarter ended 2020-09-302020-11-04acceptance time not in the bulk data set
13F-NT 0000950123-20-008395 Quarter ended 2020-06-302020-08-12acceptance time not in the bulk data set
13F-NT 0001606074-20-000015 Quarter ended 2020-03-312020-05-07acceptance time not in the bulk data set
13F-NT 0000950123-20-001658 Quarter ended 2019-12-312020-02-13acceptance time not in the bulk data set